DEVELOPMENT OF NOVEL INJECTABLE FORMULATION OF CLOPIDOGREL BY QbD APPROACH

Abstract

Clopidogrel, a poorly water-soluble drug, has been the mainstay of platelet management in acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) for over a decade. Since Clopidogrel is a prodrug and requires hepatic metabolism for activation, it exhibits a slower onset of action upon oral administration. This time-lag before the onset on the action is highly undesirable for the treatment of critical conditions such as coronary intervention, which is a medical emergency during which the rapid onset of antiplatelet action is of paramount importance. To achieve rapid onset, intravenous is the preferred route of administration; however, due to poor aqueous solubility, development of the IV formulation of Clopidogrel presents a considerable challenge. In the present investigation, the liposomal formulation of Clopidogrel was developed, which enables IV administration and may potentially provide a rapid onset of action. The formulation was prepared and optimized using 32 full factorial designs with Design Expert 11 software and evaluated for critical quality attributes (% entrapment, particle size, PDI, zeta potential and Morphology, pH/dilution induced stability and short term stability studies. The particle size of optimized formulation was 94.5 ± 2.8 nm, with PDI of 0.126 ± 0.012 and entrapment efficiency (EE) of 89.2 ± 2.1. The developed formulation was stable over a study period of 3 months at 2°-8 °C. This formulation has great potential as rapid-acting IV formulation to fulfill the unmet need in the management of cardiovascular emergency like (ACS) and PCI.

Authors and Affiliations

J. Hadia et al.

Keywords

Related Articles

EFFECT OF PIPER NIGRUM (LINN.) ON INFERTILITY INDUCED BY ETHIONAMIDE AND PARA AMINO SALICYLIC ACID IN MALE SPRAGUE-DAWLEY RATS

Tuberculosis is a global problem. The tuberculosis is the common cause of male infertility in developing countries due to the use of second-line anti-tuberculosis drugs (ATB). The experiments were conducted at Unique Bio...

IN-SILICO MOLECULAR DOCKING ANALYSIS OF ISOLATED HOMOISOFLAVANONES FROM BULBS OF LEDABOURIA REVOLUTA AS GABAA RECEPTOR INHIBITORS

γ-Aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the vertebrate central nervous system (CNS); it activates the GABAA receptors that play a role in epilepsy. Targeting GABAA receptors through specifi...

DEVELOPMENT OF NOVEL INJECTABLE FORMULATION OF CLOPIDOGREL BY QbD APPROACH

Clopidogrel, a poorly water-soluble drug, has been the mainstay of platelet management in acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) for over a decade. Since Clopidogrel is a prodrug and re...

A SIMPLE AND ECONOMICAL PROCEDURE FOR SYNTHESIS OF AMANTADINE HYDROCHLORIDE

Amantadine hydrochloride (1), a well-known antiviral drug, has been used to treat certain type-A influenza infections and been also medicated as an anti-dyskinetic agent for Parkinson’s disease. In this paper, we report...

FLOATING ORAL IN-SITU GEL, A COMPREHENSIVE APPROACH OF GASTRO-RETENTIVE DRUG DELIVERY SYSTEM: A REVIEW

Conventional oral dosage forms posses low bioavailability problems due to their rapid gastric transition from the stomach. Especially some drug which is less soluble in alkaline pH and producing local action in the stoma...

Download PDF file
  • EP ID EP581506
  • DOI 10.13040/IJPSR.0975-8232.10(6).3029-37
  • Views 74
  • Downloads 0

How To Cite

J. Hadia et al. (2019). DEVELOPMENT OF NOVEL INJECTABLE FORMULATION OF CLOPIDOGREL BY QbD APPROACH. International Journal of Pharmaceutical Sciences and Research (IJPSR), 10(6), 3029-3037. https://europub.co.uk/articles/-A-581506